Key takeaways
- Cost-conscious investors may find the VanEck fund more appealing due to its 0.36% expense ratio, which is lower than the 0.44% charged by the iShares fund.
- VanEck Pharmaceutical ETF has paid $2.14 per share over the trailing 12 months, which on its recent ~$119.21 share price works out to a 1.8% yield.
- The iShares Biotechnology ETF provides much broader diversification with 243 holdings, allocated 87% to biotechnology and 10% to life sciences.
VanEck Pharmaceutical ETF offers a lower expense ratio and a higher dividend yield than iShares Biotechnology ETF. iShares Biotechnology ETF provides broader exposure with over 200 holdings, while VanEck Pharmaceutical ETF concentrates on 26 pharmaceutical leaders.
See the latest quote, chart and news for PPH.
